Login to Your Account



Prometic Inks Four-Product Deal with Abraxis Worth up to $295M

By Jennifer Boggs


Friday, September 5, 2008
ProMetic Life Sciences Inc. entered a potential $295 million licensing agreement with Abraxis BioScience to develop four products targeting undisclosed underserved medical conditions on a worldwide basis, excluding China and Taiwan. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription